β-Lactam Susceptibility of <i>Streptococcus dysgalactiae </i>subsp. <i>equisimilis</i>

DOI Web Site 参考文献13件
  • Nakashima Natsumi
    Department of Bacteriology, Nagoya University Graduate School of Medicine, Japan
  • Jin Wanchun
    Department of Bacteriology, Nagoya University Graduate School of Medicine, Japan
  • Wachino Jun-ichi
    Department of Bacteriology, Nagoya University Graduate School of Medicine, Japan
  • Koyama Shinobu
    Miroku Medical Laboratory Inc., Japan
  • Tamai Kiyoko
    Miroku Medical Laboratory Inc., Japan
  • Arakawa Yoshichika
    Department of Bacteriology, Nagoya University Graduate School of Medicine, Japan
  • Kimura Kouji
    Department of Bacteriology, Nagoya University Graduate School of Medicine, Japan

抄録

<p>All clinical isolates of Streptococcus dysgalactiae subsp. equisimilis (SDSE) are considered susceptible to β-lactams, the first-line drugs used for SDSE infections. However, penicillin-non-susceptible SDSE has been reported from Denmark. In this study, we attempted to detect β-lactam-non-susceptible clinical isolates of SDSE in Japan. One hundred and fifty clinical isolates of S. dysgalactiae were collected in 2018, and species identification was performed using Rapid ID Strep API. The minimum inhibitory concentrations (MIC) of six β-lactams (penicillin G, oxacillin, ceftizoxime, ceftibuten, cefoxitin, and cefaclor) were determined for 85 clinical isolates of SDSE using the agar dilution method standardized by the Clinical Laboratory Standards Institute. For the 85 isolates identified as SDSE, the MIC ranges of penicillin G, oxacillin, ceftizoxime, ceftibuten, cefoxitin, and cefaclor were 0.007–0.06, 0.03–0.12, 0.015–0.06, 0.25–2, 0.12–2, and 0.06–0.5 μg/mL, respectively. None of the clinical isolates were non-susceptible to penicillin G, indicating that all 85 clinical isolates of SDSE were susceptible to β-lactams. Our findings indicate that almost all clinical isolates of SDSE in several prefectures of Japan remain susceptible to β-lactams. Nevertheless, there remains a need for continuous and careful monitoring of drug susceptibility among clinical isolates of SDSE in Japan. </p>

収録刊行物

参考文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ